Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience
Study Type – Therapy (prevalence) Level of Evidence 2b What's known on the subject? and What does the study add? Persistence with long‐term medication in chronic diseases is typically low and that for overactive bladder medication is lower than average. Sub‐optimal persistence is a major challe...
Saved in:
| Published in | BJU international Vol. 110; no. 11; pp. 1767 - 1774 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.12.2012
Wiley-Blackwell Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1464-4096 1464-410X 1464-410X |
| DOI | 10.1111/j.1464-410X.2012.11023.x |
Cover
Loading…
| Abstract | Study Type – Therapy (prevalence)
Level of Evidence 2b
What's known on the subject? and What does the study add?
Persistence with long‐term medication in chronic diseases is typically low and that for overactive bladder medication is lower than average. Sub‐optimal persistence is a major challenge for the successful management of overactive bladder.
Using UK prescription data, persistence was generally low across the range of antimuscarinics. Patients aged 60 years and above were more likely to persist with prescribed oral antimuscarinic drugs than younger patients (40–59 years). Solifenacin was consistently associated with the highest rate of persistence compared with the other antimuscarinics included in the study
OBJECTIVES
•
To describe the level of persistence for patients receiving antimuscarinics for overactive bladder (OAB) over a 12‐month period based on real prescription data from the UK.
•
To investigate patterns of persistence with oral antimuscarinic drugs prescribed for OAB, across different age groups.
PATIENTS AND METHODS
•
UK prescription data from a longitudinal patient database were analysed retrospectively to assess persistence with darifenacin, flavoxate, oxybutynin (extended release [ER] and immediate release [IR]), propiverine, solifenacin, tolterodine (ER/IR) and trospium.
•
Data were extracted from the medical records of >1 200 000 registered patients via general practice software, and anonymized prescription data were collated for all eligible patients with documented OAB (n= 4833).
•
Data were collected on patients who started treatment between January 2007 and December 2007 and were collected up to December 2008, to allow each patient a full 12‐month potential treatment period. Failure of persistence was declared after a gap of at least 1.5 times the length of the period of the most recent prescription.
•
The analysis included only patients who were new to a course of treatment (i.e. who had not been prescribed that particular treatment or dosage for at least 6 months before the study period).
RESULTS
•
The number of patients prescribed each antimuscarinic drug varied from 23 for darifenacin to 1758 for tolterodine ER.
•
The longest mean persistence was reported for solifenacin (187 days versus 77−157 days for the other treatments).
•
At 3 months, the proportions of patients still on their original treatment were: solifenacin 58%, darifenacin 52%, tolterodine ER 47%, propiverine 47%, tolterodine IR 46%, oxybutynin ER 44%, trospium 42%, oxybutynin IR 40%, flavoxate 28%.
•
At 12 months, the proportions of patients still on their original treatment were: solifenacin 35%, tolterodine ER 28%, propiverine 27%, oxybutynin ER 26%, trospium 26%, tolterodine IR 24%, oxybutynin IR 22%, darifenacin 17%, flavoxate 14%.
•
In a sub‐analysis stratified by age, patients aged ≥60 years were more likely to persist with prescribed therapy over the 12‐month period than those aged <60 years.
CONCLUSIONS
•
Twelve months after the initial prescription, persistence rates with pharmacotherapy in the context of OAB are generally low.
•
Solifenacin was associated with higher levels of persistence compared with other prescribed antimuscarinic agents.
•
Older people are more likely than younger patients to persist with prescribed therapy. Further studies are required to understand this finding and why patients are more likely to persist with one drug rather than another. |
|---|---|
| AbstractList | Study Type--Therapy (prevalence) Level of Evidence 2b. What's known on the subject? and What does the study add? Persistence with long-term medication in chronic diseases is typically low and that for overactive bladder medication is lower than average. Sub-optimal persistence is a major challenge for the successful management of overactive bladder. Using UK prescription data, persistence was generally low across the range of antimuscarinics. Patients aged 60 years and above were more likely to persist with prescribed oral antimuscarinic drugs than younger patients (40-59 years). Solifenacin was consistently associated with the highest rate of persistence compared with the other antimuscarinics included in the study
• To describe the level of persistence for patients receiving antimuscarinics for overactive bladder (OAB) over a 12-month period based on real prescription data from the UK. • To investigate patterns of persistence with oral antimuscarinic drugs prescribed for OAB, across different age groups.
• UK prescription data from a longitudinal patient database were analysed retrospectively to assess persistence with darifenacin, flavoxate, oxybutynin (extended release [ER] and immediate release [IR]), propiverine, solifenacin, tolterodine (ER/IR) and trospium. • Data were extracted from the medical records of >1,200,000 registered patients via general practice software, and anonymized prescription data were collated for all eligible patients with documented OAB (n = 4833). • Data were collected on patients who started treatment between January 2007 and December 2007 and were collected up to December 2008, to allow each patient a full 12-month potential treatment period. Failure of persistence was declared after a gap of at least 1.5 times the length of the period of the most recent prescription. • The analysis included only patients who were new to a course of treatment (i.e. who had not been prescribed that particular treatment or dosage for at least 6 months before the study period).
• The number of patients prescribed each antimuscarinic drug varied from 23 for darifenacin to 1758 for tolterodine ER. • The longest mean persistence was reported for solifenacin (187 days versus 77-157 days for the other treatments). • At 3 months, the proportions of patients still on their original treatment were: solifenacin 58%, darifenacin 52%, tolterodine ER 47%, propiverine 47%, tolterodine IR 46%, oxybutynin ER 44%, trospium 42%, oxybutynin IR 40%, flavoxate 28%. • At 12 months, the proportions of patients still on their original treatment were: solifenacin 35%, tolterodine ER 28%, propiverine 27%, oxybutynin ER 26%, trospium 26%, tolterodine IR 24%, oxybutynin IR 22%, darifenacin 17%, flavoxate 14%. • In a sub-analysis stratified by age, patients aged ≥ 60 years were more likely to persist with prescribed therapy over the 12-month period than those aged <60 years.
• Twelve months after the initial prescription, persistence rates with pharmacotherapy in the context of OAB are generally low. • Solifenacin was associated with higher levels of persistence compared with other prescribed antimuscarinic agents. • Older people are more likely than younger patients to persist with prescribed therapy. Further studies are required to understand this finding and why patients are more likely to persist with one drug rather than another. Study Type--Therapy (prevalence) Level of Evidence 2b. What's known on the subject? and What does the study add? Persistence with long-term medication in chronic diseases is typically low and that for overactive bladder medication is lower than average. Sub-optimal persistence is a major challenge for the successful management of overactive bladder. Using UK prescription data, persistence was generally low across the range of antimuscarinics. Patients aged 60 years and above were more likely to persist with prescribed oral antimuscarinic drugs than younger patients (40-59 years). Solifenacin was consistently associated with the highest rate of persistence compared with the other antimuscarinics included in the studyUNLABELLEDStudy Type--Therapy (prevalence) Level of Evidence 2b. What's known on the subject? and What does the study add? Persistence with long-term medication in chronic diseases is typically low and that for overactive bladder medication is lower than average. Sub-optimal persistence is a major challenge for the successful management of overactive bladder. Using UK prescription data, persistence was generally low across the range of antimuscarinics. Patients aged 60 years and above were more likely to persist with prescribed oral antimuscarinic drugs than younger patients (40-59 years). Solifenacin was consistently associated with the highest rate of persistence compared with the other antimuscarinics included in the study• To describe the level of persistence for patients receiving antimuscarinics for overactive bladder (OAB) over a 12-month period based on real prescription data from the UK. • To investigate patterns of persistence with oral antimuscarinic drugs prescribed for OAB, across different age groups.OBJECTIVES• To describe the level of persistence for patients receiving antimuscarinics for overactive bladder (OAB) over a 12-month period based on real prescription data from the UK. • To investigate patterns of persistence with oral antimuscarinic drugs prescribed for OAB, across different age groups.• UK prescription data from a longitudinal patient database were analysed retrospectively to assess persistence with darifenacin, flavoxate, oxybutynin (extended release [ER] and immediate release [IR]), propiverine, solifenacin, tolterodine (ER/IR) and trospium. • Data were extracted from the medical records of >1,200,000 registered patients via general practice software, and anonymized prescription data were collated for all eligible patients with documented OAB (n = 4833). • Data were collected on patients who started treatment between January 2007 and December 2007 and were collected up to December 2008, to allow each patient a full 12-month potential treatment period. Failure of persistence was declared after a gap of at least 1.5 times the length of the period of the most recent prescription. • The analysis included only patients who were new to a course of treatment (i.e. who had not been prescribed that particular treatment or dosage for at least 6 months before the study period).PATIENTS AND METHODS• UK prescription data from a longitudinal patient database were analysed retrospectively to assess persistence with darifenacin, flavoxate, oxybutynin (extended release [ER] and immediate release [IR]), propiverine, solifenacin, tolterodine (ER/IR) and trospium. • Data were extracted from the medical records of >1,200,000 registered patients via general practice software, and anonymized prescription data were collated for all eligible patients with documented OAB (n = 4833). • Data were collected on patients who started treatment between January 2007 and December 2007 and were collected up to December 2008, to allow each patient a full 12-month potential treatment period. Failure of persistence was declared after a gap of at least 1.5 times the length of the period of the most recent prescription. • The analysis included only patients who were new to a course of treatment (i.e. who had not been prescribed that particular treatment or dosage for at least 6 months before the study period).• The number of patients prescribed each antimuscarinic drug varied from 23 for darifenacin to 1758 for tolterodine ER. • The longest mean persistence was reported for solifenacin (187 days versus 77-157 days for the other treatments). • At 3 months, the proportions of patients still on their original treatment were: solifenacin 58%, darifenacin 52%, tolterodine ER 47%, propiverine 47%, tolterodine IR 46%, oxybutynin ER 44%, trospium 42%, oxybutynin IR 40%, flavoxate 28%. • At 12 months, the proportions of patients still on their original treatment were: solifenacin 35%, tolterodine ER 28%, propiverine 27%, oxybutynin ER 26%, trospium 26%, tolterodine IR 24%, oxybutynin IR 22%, darifenacin 17%, flavoxate 14%. • In a sub-analysis stratified by age, patients aged ≥ 60 years were more likely to persist with prescribed therapy over the 12-month period than those aged <60 years.RESULTS• The number of patients prescribed each antimuscarinic drug varied from 23 for darifenacin to 1758 for tolterodine ER. • The longest mean persistence was reported for solifenacin (187 days versus 77-157 days for the other treatments). • At 3 months, the proportions of patients still on their original treatment were: solifenacin 58%, darifenacin 52%, tolterodine ER 47%, propiverine 47%, tolterodine IR 46%, oxybutynin ER 44%, trospium 42%, oxybutynin IR 40%, flavoxate 28%. • At 12 months, the proportions of patients still on their original treatment were: solifenacin 35%, tolterodine ER 28%, propiverine 27%, oxybutynin ER 26%, trospium 26%, tolterodine IR 24%, oxybutynin IR 22%, darifenacin 17%, flavoxate 14%. • In a sub-analysis stratified by age, patients aged ≥ 60 years were more likely to persist with prescribed therapy over the 12-month period than those aged <60 years.• Twelve months after the initial prescription, persistence rates with pharmacotherapy in the context of OAB are generally low. • Solifenacin was associated with higher levels of persistence compared with other prescribed antimuscarinic agents. • Older people are more likely than younger patients to persist with prescribed therapy. Further studies are required to understand this finding and why patients are more likely to persist with one drug rather than another.CONCLUSIONS• Twelve months after the initial prescription, persistence rates with pharmacotherapy in the context of OAB are generally low. • Solifenacin was associated with higher levels of persistence compared with other prescribed antimuscarinic agents. • Older people are more likely than younger patients to persist with prescribed therapy. Further studies are required to understand this finding and why patients are more likely to persist with one drug rather than another. Study Type – Therapy (prevalence) Level of Evidence 2b What's known on the subject? and What does the study add? Persistence with long‐term medication in chronic diseases is typically low and that for overactive bladder medication is lower than average. Sub‐optimal persistence is a major challenge for the successful management of overactive bladder. Using UK prescription data, persistence was generally low across the range of antimuscarinics. Patients aged 60 years and above were more likely to persist with prescribed oral antimuscarinic drugs than younger patients (40–59 years). Solifenacin was consistently associated with the highest rate of persistence compared with the other antimuscarinics included in the study OBJECTIVES • To describe the level of persistence for patients receiving antimuscarinics for overactive bladder (OAB) over a 12‐month period based on real prescription data from the UK. • To investigate patterns of persistence with oral antimuscarinic drugs prescribed for OAB, across different age groups. PATIENTS AND METHODS • UK prescription data from a longitudinal patient database were analysed retrospectively to assess persistence with darifenacin, flavoxate, oxybutynin (extended release [ER] and immediate release [IR]), propiverine, solifenacin, tolterodine (ER/IR) and trospium. • Data were extracted from the medical records of >1 200 000 registered patients via general practice software, and anonymized prescription data were collated for all eligible patients with documented OAB (n= 4833). • Data were collected on patients who started treatment between January 2007 and December 2007 and were collected up to December 2008, to allow each patient a full 12‐month potential treatment period. Failure of persistence was declared after a gap of at least 1.5 times the length of the period of the most recent prescription. • The analysis included only patients who were new to a course of treatment (i.e. who had not been prescribed that particular treatment or dosage for at least 6 months before the study period). RESULTS • The number of patients prescribed each antimuscarinic drug varied from 23 for darifenacin to 1758 for tolterodine ER. • The longest mean persistence was reported for solifenacin (187 days versus 77−157 days for the other treatments). • At 3 months, the proportions of patients still on their original treatment were: solifenacin 58%, darifenacin 52%, tolterodine ER 47%, propiverine 47%, tolterodine IR 46%, oxybutynin ER 44%, trospium 42%, oxybutynin IR 40%, flavoxate 28%. • At 12 months, the proportions of patients still on their original treatment were: solifenacin 35%, tolterodine ER 28%, propiverine 27%, oxybutynin ER 26%, trospium 26%, tolterodine IR 24%, oxybutynin IR 22%, darifenacin 17%, flavoxate 14%. • In a sub‐analysis stratified by age, patients aged ≥60 years were more likely to persist with prescribed therapy over the 12‐month period than those aged <60 years. CONCLUSIONS • Twelve months after the initial prescription, persistence rates with pharmacotherapy in the context of OAB are generally low. • Solifenacin was associated with higher levels of persistence compared with other prescribed antimuscarinic agents. • Older people are more likely than younger patients to persist with prescribed therapy. Further studies are required to understand this finding and why patients are more likely to persist with one drug rather than another. Study Type - Therapy (prevalence) Level of Evidence 2b What's known on the subject? and What does the study add? Persistence with long-term medication in chronic diseases is typically low and that for overactive bladder medication is lower than average. Sub-optimal persistence is a major challenge for the successful management of overactive bladder. Using UK prescription data, persistence was generally low across the range of antimuscarinics. Patients aged 60 years and above were more likely to persist with prescribed oral antimuscarinic drugs than younger patients (40-59 years). Solifenacin was consistently associated with the highest rate of persistence compared with the other antimuscarinics included in the study OBJECTIVES * To describe the level of persistence for patients receiving antimuscarinics for overactive bladder (OAB) over a 12-month period based on real prescription data from the UK. * To investigate patterns of persistence with oral antimuscarinic drugs prescribed for OAB, across different age groups. PATIENTS AND METHODS * UK prescription data from a longitudinal patient database were analysed retrospectively to assess persistence with darifenacin, flavoxate, oxybutynin (extended release [ER] and immediate release [IR]), propiverine, solifenacin, tolterodine (ER/IR) and trospium. * Data were extracted from the medical records of >1 200 000 registered patients via general practice software, and anonymized prescription data were collated for all eligible patients with documented OAB (n= 4833). * Data were collected on patients who started treatment between January 2007 and December 2007 and were collected up to December 2008, to allow each patient a full 12-month potential treatment period. Failure of persistence was declared after a gap of at least 1.5 times the length of the period of the most recent prescription. * The analysis included only patients who were new to a course of treatment (i.e. who had not been prescribed that particular treatment or dosage for at least 6 months before the study period). RESULTS * The number of patients prescribed each antimuscarinic drug varied from 23 for darifenacin to 1758 for tolterodine ER. * The longest mean persistence was reported for solifenacin (187 days versus 77-157 days for the other treatments). * At 3 months, the proportions of patients still on their original treatment were: solifenacin 58%, darifenacin 52%, tolterodine ER 47%, propiverine 47%, tolterodine IR 46%, oxybutynin ER 44%, trospium 42%, oxybutynin IR 40%, flavoxate 28%. * At 12 months, the proportions of patients still on their original treatment were: solifenacin 35%, tolterodine ER 28%, propiverine 27%, oxybutynin ER 26%, trospium 26%, tolterodine IR 24%, oxybutynin IR 22%, darifenacin 17%, flavoxate 14%. * In a sub-analysis stratified by age, patients aged ≥60 years were more likely to persist with prescribed therapy over the 12-month period than those aged <60 years. CONCLUSIONS * Twelve months after the initial prescription, persistence rates with pharmacotherapy in the context of OAB are generally low. * Solifenacin was associated with higher levels of persistence compared with other prescribed antimuscarinic agents. * Older people are more likely than younger patients to persist with prescribed therapy. Further studies are required to understand this finding and why patients are more likely to persist with one drug rather than another. |
| Author | Compion, Gerhard Fahey, Amanda Siddiqui, Emad Wagg, Adrian |
| Author_xml | – sequence: 1 givenname: Adrian surname: Wagg fullname: Wagg, Adrian – sequence: 2 givenname: Gerhard surname: Compion fullname: Compion, Gerhard – sequence: 3 givenname: Amanda surname: Fahey fullname: Fahey, Amanda – sequence: 4 givenname: Emad surname: Siddiqui fullname: Siddiqui, Emad |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26710543$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22409769$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkVuLFDEQhYOsuBf9CxIQwZcZc5t0tw-CLu4d9MEB8SVUJxU2Q093m3Tvzvx707szCvu0eUlx8tWpUOeYHLRdi4RQzuY8n4-rOVdazRRnv-aCcZFVJuR884Ic_Xs42Nes0ofkOKUVY1nQi1fkUIisFro6Ir9_YEwhDdhapPdhuKV9xGRjqNFRaIewHpOFGNpg6XCLEfot9V2k3V2u7RDukNYNOIfxEwW6vKa46TGGye41eemhSfhmd5-Q5dm3n6cXs5vv55enX25mVolSzlzJalkiB8FVUXj0QgNXtfMoQSsGQkCt3YJJhLp0zlW8LiuvhPC4qDiCPCEfHn372P0ZMQ1mHZLFpoEWuzEZLmTBKl6VZUbfPUFX3Rjb_DvDC11UWkheZertjhrrNTrTx7CGuDX7rWXg_Q6AvJzGR2htSP85XXC2UDJznx85G7uUInpjwwBD6NohQmgMZ2aK06zMlJSZUjNTnOYhTrPJBuUTg_2MZ7TuZt-HBrfP7jNfr5YPpfwLTCm3Ng |
| CODEN | BJINFO |
| CitedBy_id | crossref_primary_10_1097_MOU_0000000000000108 crossref_primary_10_1111_luts_12088 crossref_primary_10_1002_nau_22383 crossref_primary_10_1016_j_juro_2013_08_082 crossref_primary_10_1080_13696998_2016_1204307 crossref_primary_10_1002_nau_22943 crossref_primary_10_1080_14737167_2016_1203258 crossref_primary_10_1007_s40272_017_0249_x crossref_primary_10_1111_ijcp_12447 crossref_primary_10_1016_j_juro_2014_11_094 crossref_primary_10_1002_nau_22707 crossref_primary_10_1007_s00192_017_3492_3 crossref_primary_10_2147_IJWH_S372597 crossref_primary_10_1007_s00210_012_0821_4 crossref_primary_10_1111_iju_13498 crossref_primary_10_1111_luts_12417 crossref_primary_10_1080_03007995_2021_1885366 crossref_primary_10_3834_uij_1944_5784_2013_12_02 crossref_primary_10_3389_fphar_2021_756582 crossref_primary_10_1080_17512433_2017_1275570 crossref_primary_10_1007_s11255_018_1869_y crossref_primary_10_1016_j_aju_2015_07_003 crossref_primary_10_1111_ijcp_12693 crossref_primary_10_18553_jmcp_2018_24_1_65 crossref_primary_10_1111_bju_12006 crossref_primary_10_1002_nau_23256 crossref_primary_10_1080_14740338_2018_1453496 crossref_primary_10_1111_luts_12188 crossref_primary_10_1007_s00192_019_04193_4 crossref_primary_10_1186_s12894_017_0216_4 crossref_primary_10_1002_nau_22603 crossref_primary_10_1111_ijcp_12783 crossref_primary_10_1016_j_archger_2018_09_005 crossref_primary_10_1038_nrurol_2015_183 crossref_primary_10_1177_2051415817706045 crossref_primary_10_1016_j_acuro_2013_05_003 crossref_primary_10_1080_03007995_2017_1419170 crossref_primary_10_1371_journal_pone_0147137 crossref_primary_10_1007_s11934_012_0262_0 crossref_primary_10_1177_1756287215591763 crossref_primary_10_4111_icu_2017_58_2_109 crossref_primary_10_5213_inj_1632520_260 crossref_primary_10_1016_j_eururo_2013_11_010 crossref_primary_10_1080_14656566_2022_2126311 crossref_primary_10_1111_iju_15530 crossref_primary_10_1016_j_semerg_2016_05_006 crossref_primary_10_1136_bmjopen_2013_003297 crossref_primary_10_1007_s00345_014_1244_2 crossref_primary_10_1111_ijcp_12433 crossref_primary_10_12968_bjon_2020_29_18_S30 crossref_primary_10_1517_14728214_2013_823156 crossref_primary_10_1016_j_eururo_2017_11_002 crossref_primary_10_1590_S1677_5538_IBJU_2013_04_09 crossref_primary_10_1186_s12916_017_0828_2 crossref_primary_10_1016_j_mpmed_2016_10_001 crossref_primary_10_1111_ijcp_13616 crossref_primary_10_1016_j_maturitas_2019_04_216 crossref_primary_10_1186_s12894_021_00881_w crossref_primary_10_1002_nau_23315 crossref_primary_10_1016_j_euf_2023_09_017 crossref_primary_10_1111_ans_19309 crossref_primary_10_1111_iju_13174 crossref_primary_10_1002_nau_25040 crossref_primary_10_1111_luts_12459 crossref_primary_10_1002_nau_24079 crossref_primary_10_1111_bju_13882 crossref_primary_10_1517_14656566_2013_796930 crossref_primary_10_3389_fphys_2025_1534517 crossref_primary_10_1016_j_eururo_2012_10_016 crossref_primary_10_1186_1471_2490_13_45 crossref_primary_10_1177_1756287215614237 crossref_primary_10_2217_cpr_14_38 crossref_primary_10_1097_CU9_0000000000000037 crossref_primary_10_1016_j_ejogrb_2016_12_030 crossref_primary_10_1007_s11255_021_02802_0 crossref_primary_10_3390_molecules25061384 crossref_primary_10_1007_s11884_019_00501_2 crossref_primary_10_1080_21681805_2019_1619832 crossref_primary_10_1111_jog_13541 crossref_primary_10_1016_j_cct_2016_09_005 crossref_primary_10_3390_ph17010116 crossref_primary_10_1016_j_maturitas_2013_07_003 crossref_primary_10_1080_14656566_2016_1186645 crossref_primary_10_1097_MBP_0000000000000320 crossref_primary_10_1007_s00120_014_3629_7 crossref_primary_10_2217_WHE_15_31 crossref_primary_10_1016_j_acuroe_2013_03_002 crossref_primary_10_1016_j_urology_2019_06_002 crossref_primary_10_1093_ageing_aft214 crossref_primary_10_1177_1756287217702797 crossref_primary_10_1016_j_urols_2017_05_006 crossref_primary_10_1186_s12894_017_0226_2 crossref_primary_10_1111_bju_15040 crossref_primary_10_1136_dtb_2013_8_0196 crossref_primary_10_1111_ijcp_12996 crossref_primary_10_1007_s40266_013_0145_1 crossref_primary_10_1016_j_jgyn_2014_06_011 crossref_primary_10_1080_14656566_2023_2264183 crossref_primary_10_1097_SPV_0000000000000215 crossref_primary_10_1111_ijcp_12194 crossref_primary_10_1186_s12913_020_05315_1 crossref_primary_10_5317_wjog_v2_i4_65 crossref_primary_10_1016_j_eurger_2017_04_002 crossref_primary_10_1016_j_semerg_2015_10_006 crossref_primary_10_1111_iju_13422 crossref_primary_10_1177_2042098616659412 crossref_primary_10_1007_s11136_015_1216_z crossref_primary_10_1111_luts_12247 crossref_primary_10_1002_nau_23993 crossref_primary_10_1185_03007995_2014_968704 crossref_primary_10_1002_nau_22780 crossref_primary_10_1007_s11934_013_0335_8 crossref_primary_10_1002_nau_22544 crossref_primary_10_1007_s12325_024_03019_0 crossref_primary_10_1016_j_purol_2013_09_020 crossref_primary_10_1097_SPV_0000000000000744 crossref_primary_10_1248_cpb_c19_00552 crossref_primary_10_1177_1756287215589250 crossref_primary_10_1517_13543784_2014_925877 crossref_primary_10_1038_s41598_018_27617_5 crossref_primary_10_1517_13543784_2015_1076390 crossref_primary_10_2147_IJWH_S369588 crossref_primary_10_1016_j_jfma_2018_05_006 crossref_primary_10_1007_s00129_017_4031_5 crossref_primary_10_1002_nau_23980 crossref_primary_10_2174_1389450121666200716202103 crossref_primary_10_1111_bju_13162 crossref_primary_10_1111_luts_12253 crossref_primary_10_1111_luts_12382 crossref_primary_10_1111_luts_12141 crossref_primary_10_1186_s12894_018_0390_z crossref_primary_10_1111_jog_14708 crossref_primary_10_1016_j_juro_2013_10_046 crossref_primary_10_1111_iju_13764 crossref_primary_10_1517_14656566_2014_898752 crossref_primary_10_1016_j_acuroe_2015_09_008 crossref_primary_10_2217_WHE_14_1 crossref_primary_10_12688_f1000research_7131_1 crossref_primary_10_1002_nau_24741 crossref_primary_10_1007_s11255_018_1907_9 crossref_primary_10_1002_nau_23774 crossref_primary_10_1111_ijcp_12824 crossref_primary_10_1002_nau_25397 crossref_primary_10_1007_s11934_015_0531_9 crossref_primary_10_1517_14656566_2016_1145662 crossref_primary_10_1002_nau_23413 crossref_primary_10_1517_17460441_2014_892923 crossref_primary_10_1159_000507230 crossref_primary_10_3390_toxins15010030 crossref_primary_10_1002_nau_22795 crossref_primary_10_1111_luts_12474 crossref_primary_10_1007_s00192_021_04785_z crossref_primary_10_1177_17562872211039034 crossref_primary_10_1016_j_ejogrb_2018_01_002 crossref_primary_10_1007_s11884_014_0247_6 crossref_primary_10_1016_j_eururo_2017_01_037 crossref_primary_10_1517_13543784_2015_1001836 crossref_primary_10_1186_s12877_017_0690_2 crossref_primary_10_3111_13696998_2014_995300 crossref_primary_10_1016_j_acuro_2013_03_005 crossref_primary_10_1016_j_maturitas_2014_08_009 crossref_primary_10_1038_s41598_020_60967_7 crossref_primary_10_1111_bju_12649 crossref_primary_10_1021_acs_jmedchem_5b00638 crossref_primary_10_1038_s41598_024_67326_w crossref_primary_10_1021_acs_jproteome_7b00568 crossref_primary_10_1186_s12894_018_0376_x crossref_primary_10_1080_20016689_2018_1438721 crossref_primary_10_1007_s40261_014_0240_z crossref_primary_10_1016_j_surge_2022_09_004 crossref_primary_10_3109_13697137_2014_947257 crossref_primary_10_1002_nau_23276 crossref_primary_10_1016_j_jval_2015_05_011 crossref_primary_10_1016_j_urology_2015_01_002 crossref_primary_10_1016_j_acuro_2015_09_004 crossref_primary_10_1002_nau_22505 crossref_primary_10_1073_pnas_1901655116 crossref_primary_10_1111_iju_13218 crossref_primary_10_1007_s00192_014_2585_5 crossref_primary_10_1177_2053369120927112 crossref_primary_10_1517_14740338_2016_1165663 crossref_primary_10_1177_1756287217742837 crossref_primary_10_1016_j_tcmj_2015_12_003 crossref_primary_10_1002_nau_23944 crossref_primary_10_1002_nau_22978 crossref_primary_10_1038_nrurol_2017_67 crossref_primary_10_1124_pharmrev_121_000523 crossref_primary_10_3111_13696998_2014_941066 crossref_primary_10_1097_SPV_0000000000000277 crossref_primary_10_1177_0391560319859785 crossref_primary_10_1016_j_eururo_2017_03_040 crossref_primary_10_1016_j_maturitas_2013_01_012 crossref_primary_10_1080_14656566_2023_2237406 crossref_primary_10_1188_15_S1_CJON_6_30 crossref_primary_10_1002_nau_23050 crossref_primary_10_1111_iju_12355 crossref_primary_10_1111_bju_15555 crossref_primary_10_4103_UROS_UROS_2_18 crossref_primary_10_1186_s12906_018_2101_4 crossref_primary_10_1002_nau_24824 crossref_primary_10_1111_luts_12153 crossref_primary_10_1002_nau_23974 crossref_primary_10_1002_nau_23852 crossref_primary_10_1097_AOG_0000000000003320 crossref_primary_10_1111_luts_12391 crossref_primary_10_1111_ggi_13465 crossref_primary_10_1111_iju_13558 crossref_primary_10_1007_s11255_020_02412_2 crossref_primary_10_1038_s41598_022_23795_5 crossref_primary_10_1371_journal_pone_0204456 crossref_primary_10_1111_bju_13945 crossref_primary_10_1097_GME_0000000000000730 crossref_primary_10_1111_bju_12730 crossref_primary_10_4111_icu_2016_57_2_84 crossref_primary_10_1016_j_euf_2018_03_011 crossref_primary_10_1007_s00192_016_2945_4 crossref_primary_10_1016_j_jns_2017_11_028 crossref_primary_10_1007_s00192_016_3118_1 crossref_primary_10_1186_s12894_015_0031_8 crossref_primary_10_1016_j_eururo_2012_08_060 crossref_primary_10_1038_nrurol_2013_143 crossref_primary_10_1016_j_purol_2015_01_006 crossref_primary_10_1111_ijun_12058 crossref_primary_10_1136_bmjopen_2018_021889 crossref_primary_10_1016_j_purol_2013_02_001 crossref_primary_10_1021_acs_jmedchem_6b01197 crossref_primary_10_1016_j_acuroe_2013_05_005 crossref_primary_10_1016_j_ejogrb_2017_01_028 crossref_primary_10_1055_s_0043_1770093 crossref_primary_10_1097_MD_0000000000032052 crossref_primary_10_1093_ageing_afu017 |
| Cites_doi | 10.1016/S0149-2918(02)85137-2 10.1016/j.juro.2009.11.026 10.1111/j.1751-7176.2010.00356.x 10.1111/j.1524-4733.2005.00041.x 10.1111/j.1742-1241.2006.01059.x 10.1056/NEJMra032662 10.1016/j.bone.2005.10.022 10.18553/jmcp.2008.14.3.291 10.1007/s00228-010-0917-z 10.1016/j.urology.2010.03.097 10.1001/jama.285.4.437 10.1002/nau.20737 10.18553/jmcp.2009.15.9.728 10.1136/bmj.39553.670231.25 10.1111/j.1464-410X.2006.06035.x 10.1111/j.1524-4733.2007.00213.x 10.1007/s00228-008-0600-9 10.1046/j.1464-410x.2001.02228.x 10.1038/nrurol.2010.147 10.1016/S0002-9343(03)00362-0 10.3410/M2-9 10.1111/j.1464-410X.2009.09036.x 10.1111/j.1471-0528.1997.tb12054.x 10.1111/j.1464-410X.2009.09035.x 10.1016/j.urology.2010.07.275 10.1097/01.hjh.0000186832.41125.8a 10.1016/S0090-4295(99)00492-6 10.1111/j.1368-5031.2005.00617.x 10.1007/BF02850081 10.1111/j.1464-410X.2004.05255.x 10.1111/j.1464-410X.2008.07769.x 10.1016/j.eururo.2004.11.004 10.1111/j.1742-1241.2010.02626.x 10.1007/s00198-009-0930-1 |
| ContentType | Journal Article |
| Copyright | 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL 2014 INIST-CNRS 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL. BJUI © 2012 BJU International |
| Copyright_xml | – notice: 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL – notice: 2014 INIST-CNRS – notice: 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL. – notice: BJUI © 2012 BJU International |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7X8 |
| DOI | 10.1111/j.1464-410X.2012.11023.x |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Calcium & Calcified Tissue Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1464-410X |
| EndPage | 1774 |
| ExternalDocumentID | 3963137161 22409769 26710543 10_1111_j_1464_410X_2012_11023_x BJU11023 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom Europe |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAYXX AEYWJ AGHNM AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7QP 7X8 |
| ID | FETCH-LOGICAL-c4283-d80b38e1a21477fef26a14bdfe3a640a22ab6d503eab8ddd91b89f422fe591ea3 |
| IEDL.DBID | DR2 |
| ISSN | 1464-4096 1464-410X |
| IngestDate | Fri Jul 11 09:06:45 EDT 2025 Fri Jul 25 04:23:40 EDT 2025 Mon Jul 21 06:02:24 EDT 2025 Mon Jul 21 09:17:31 EDT 2025 Thu Apr 24 23:08:19 EDT 2025 Tue Jul 01 03:49:55 EDT 2025 Wed Jan 22 16:38:00 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | Drug Nephrology Urinary system disease Urinary tract disease Urology Persistence Anticholinergic agent Cholinergic receptor Treatment Solifenacin Antimuscarinic agent Overactive bladder Bladder disease Muscarinic receptor Antagonist antimuscarinic drugs |
| Language | English |
| License | CC BY 4.0 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4283-d80b38e1a21477fef26a14bdfe3a640a22ab6d503eab8ddd91b89f422fe591ea3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 22409769 |
| PQID | 1767962319 |
| PQPubID | 1026371 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1237091988 proquest_journals_1767962319 pubmed_primary_22409769 pascalfrancis_primary_26710543 crossref_citationtrail_10_1111_j_1464_410X_2012_11023_x crossref_primary_10_1111_j_1464_410X_2012_11023_x wiley_primary_10_1111_j_1464_410X_2012_11023_x_BJU11023 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | December 2012 |
| PublicationDateYYYYMMDD | 2012-12-01 |
| PublicationDate_xml | – month: 12 year: 2012 text: December 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England – name: Edgecliff |
| PublicationTitle | BJU international |
| PublicationTitleAlternate | BJU Int |
| PublicationYear | 2012 |
| Publisher | Blackwell Publishing Ltd Wiley-Blackwell Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley-Blackwell – name: Wiley Subscription Services, Inc |
| References | 2010; 12 2010; 76 2006; 97 2001; 285 2009; 65 2000; 6 2010; 105 2010 2006; 38 2009 2008; 14 2006 2010; 183 2008; 11 2003 2008; 102 2003; 115 2005; 22 2005; 23 2009; 28 2001; 87 2005; 47 2006; 60 1997; 104 2010; 21 2001; 7 2004; 350 2000; 55 2002; 24 2005; 8 2005; 95 2011; 65 2008; 336 2011; 67 2005; 59 2010; 2 2010; 7 2003; 20 2005; 11 2009; 15 e_1_2_8_27_2 e_1_2_8_29_2 e_1_2_8_23_2 e_1_2_8_46_2 e_1_2_8_24_2 e_1_2_8_45_2 e_1_2_8_25_2 e_1_2_8_48_2 e_1_2_8_47_2 Brown JS (e_1_2_8_9_2) 2000; 6 Mullins CD (e_1_2_8_28_2) 2005; 11 e_1_2_8_2_2 e_1_2_8_4_2 e_1_2_8_3_2 e_1_2_8_6_2 e_1_2_8_5_2 e_1_2_8_8_2 e_1_2_8_7_2 e_1_2_8_42_2 e_1_2_8_20_2 e_1_2_8_41_2 e_1_2_8_44_2 e_1_2_8_22_2 e_1_2_8_43_2 e_1_2_8_40_2 e_1_2_8_16_2 Schabert VF (e_1_2_8_21_2) 2009; 15 e_1_2_8_39_2 e_1_2_8_17_2 e_1_2_8_38_2 Smith AL (e_1_2_8_11_2) 2010; 2 e_1_2_8_18_2 Nabi G (e_1_2_8_13_2) 2006 e_1_2_8_19_2 e_1_2_8_12_2 e_1_2_8_35_2 e_1_2_8_34_2 e_1_2_8_14_2 e_1_2_8_37_2 e_1_2_8_15_2 e_1_2_8_36_2 Shaya FT (e_1_2_8_26_2) 2005; 11 McGhan WF (e_1_2_8_10_2) 2001; 7 e_1_2_8_31_2 e_1_2_8_30_2 e_1_2_8_33_2 e_1_2_8_32_2 24029333 - J Urol. 2013 Oct;190(4):1328 |
| References_xml | – volume: 59 start-page: 931 year: 2005 end-page: 7 article-title: Persistence with antimuscarinic therapy in patients with overactive bladder publication-title: Int J Clin Pract – year: 2009 – volume: 105 start-page: 1276 year: 2010 end-page: 82 article-title: Patient‐reported reasons for discontinuing overactive bladder medication publication-title: BJU Int – volume: 115 start-page: 209 year: 2003 end-page: 16 article-title: Early discontinuation of treatment for osteoporosis publication-title: Am J Med – volume: 6 start-page: S574 year: 2000 end-page: 9 article-title: Comorbidities associated with overactive bladder publication-title: Am J Manag Care – volume: 15 start-page: 728 year: 2009 end-page: 40 article-title: Comparing adherence and persistence across 6 chronic medication classes publication-title: J Manag Care Pharm – volume: 47 start-page: 376 year: 2005 end-page: 84 article-title: Long‐term open‐label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome publication-title: Eur Urol – volume: 11 start-page: 44 year: 2008 end-page: 7 article-title: Medication compliance and persistence: terminology and definitions publication-title: Value Health – volume: 76 start-page: 1350 year: 2010 end-page: 7 article-title: Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder publication-title: Urology – year: 2003 – volume: 105 start-page: 1283 year: 2010 end-page: 90 article-title: Predictors of discontinuing overactive bladder medications publication-title: BJU Int – volume: 38 start-page: 922 year: 2006 end-page: 8 article-title: Assessment of compliance with osteoporosis treatment and its consequences in a managed care population publication-title: Bone – volume: 11 start-page: S121 year: 2005 end-page: 9 article-title: Persistence with overactive bladder pharmacotherapy in a Medicaid population publication-title: Am J Manag Care – volume: 65 start-page: 309 year: 2009 end-page: 14 article-title: Persistence of antimuscarinic drug use publication-title: Eur J Clin Pharmacol – volume: 14 start-page: 291 year: 2008 end-page: 301 article-title: Persistence, adherence, and switch rates among extended‐release and immediate‐release overactive bladder medications in a regional managed care plan publication-title: J Manag Care Pharm – volume: 12 start-page: 757 year: 2010 end-page: 64 article-title: ASH position paper: adherence and persistence with taking medication to control high blood pressure publication-title: J Clin Hypertens (Greenwich) – volume: 15 start-page: S118 year: 2009 end-page: 22 article-title: Challenges for managing overactive bladder and guidance for patient support publication-title: Am J Manag Care – volume: 336 start-page: 1114 year: 2008 end-page: 7 article-title: Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories publication-title: BMJ – volume: 23 start-page: 2093 year: 2005 end-page: 100 article-title: Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care publication-title: J Hypertens – volume: 350 start-page: 786 year: 2004 end-page: 99 article-title: Management of overactive bladder publication-title: N Engl J Med – year: 2010 – volume: 28 start-page: 287 year: 2009 article-title: Reviewing the ICS 2002 terminology report: the ongoing debate publication-title: Neurourol Urodyn – volume: 20 start-page: 327 year: 2003 end-page: 36 article-title: Prevalence and burden of overactive bladder in the United States publication-title: World J Urol – start-page: CD003781 issue: 4 year: 2006 article-title: Anticholinergic drugs versus placebo for overactive bladder syndrome in adults publication-title: Cochrane Database Syst Rev – volume: 95 start-page: 81 year: 2005 end-page: 5 article-title: Improved quality of life in patients with overactive bladder symptoms treated with solifenacin publication-title: BJU Int – volume: 8 start-page: 495 year: 2005 end-page: 505 article-title: Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program publication-title: Value Health – volume: 104 start-page: 988 year: 1997 end-page: 93 article-title: A medium‐term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance publication-title: Br J Obstet Gynaecol – volume: 65 start-page: 567 year: 2011 end-page: 85 article-title: Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature publication-title: Int J Clin Pract – volume: 7 start-page: S62 year: 2001 end-page: 75 article-title: Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder publication-title: Am J Manag Care – volume: 97 start-page: 540 year: 2006 end-page: 6 article-title: Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment publication-title: BJU Int – volume: 87 start-page: 760 year: 2001 end-page: 6 article-title: How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study publication-title: BJU Int – volume: 60 start-page: 896 year: 2006 end-page: 905 article-title: Treatment persistence with once‐monthly ibandronate and patient support vs. once‐weekly alendronate: results from the PERSIST study publication-title: Int J Clin Pract – start-page: 1 end-page: 7 – volume: 22 start-page: 313 year: 2005 end-page: 56 article-title: Medication adherence and persistence: a comprehensive review publication-title: Adv Ther – volume: 11 start-page: S101 year: 2005 end-page: 2 article-title: New perspectives on overactive bladder: quality of life impact, medication persistency, and treatment costs publication-title: Am J Manag Care – volume: 183 start-page: 1077 year: 2010 end-page: 81 article-title: Overactive bladder medication adherence when medication is free to patients publication-title: J Urol – volume: 67 start-page: 535 year: 2011 end-page: 6 article-title: Low persistence of anticholinergic drug use in Sweden publication-title: Eur J Clin Pharmacol – volume: 21 start-page: 145 year: 2010 end-page: 55 article-title: Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis publication-title: Osteoporos Int – volume: 55 start-page: 33 year: 2000 end-page: 46 article-title: Muscarinic receptor antagonists in the treatment of overactive bladder publication-title: Urology – volume: 2 start-page: 9 year: 2010 article-title: Recent advances in management of bladder overactivity publication-title: F1000 Med Rep – volume: 24 start-page: 616 year: 2002 end-page: 28 article-title: A multicenter, prospective, open‐label study of tolterodine extended‐release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT) publication-title: Clin Ther – volume: 7 start-page: 572 year: 2010 end-page: 82 article-title: Management of overactive bladder publication-title: Nat Rev Urol – volume: 285 start-page: 437 year: 2001 end-page: 43 article-title: Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas publication-title: JAMA – volume: 102 start-page: 774 year: 2008 end-page: 9 article-title: A review of adherence to drug therapy in patients with overactive bladder publication-title: BJU Int – ident: e_1_2_8_15_2 doi: 10.1016/S0149-2918(02)85137-2 – ident: e_1_2_8_27_2 doi: 10.1016/j.juro.2009.11.026 – volume: 7 start-page: S62 year: 2001 ident: e_1_2_8_10_2 article-title: Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder publication-title: Am J Manag Care – ident: e_1_2_8_19_2 doi: 10.1111/j.1751-7176.2010.00356.x – ident: e_1_2_8_22_2 doi: 10.1111/j.1524-4733.2005.00041.x – ident: e_1_2_8_24_2 – ident: e_1_2_8_48_2 doi: 10.1111/j.1742-1241.2006.01059.x – ident: e_1_2_8_8_2 doi: 10.1056/NEJMra032662 – volume: 15 start-page: S118 year: 2009 ident: e_1_2_8_21_2 article-title: Challenges for managing overactive bladder and guidance for patient support publication-title: Am J Manag Care – ident: e_1_2_8_38_2 doi: 10.1016/j.bone.2005.10.022 – ident: e_1_2_8_43_2 – ident: e_1_2_8_46_2 – ident: e_1_2_8_17_2 doi: 10.18553/jmcp.2008.14.3.291 – ident: e_1_2_8_35_2 doi: 10.1007/s00228-010-0917-z – ident: e_1_2_8_45_2 doi: 10.1016/j.urology.2010.03.097 – ident: e_1_2_8_30_2 doi: 10.1001/jama.285.4.437 – ident: e_1_2_8_3_2 doi: 10.1002/nau.20737 – volume: 11 start-page: S101 year: 2005 ident: e_1_2_8_28_2 article-title: New perspectives on overactive bladder: quality of life impact, medication persistency, and treatment costs publication-title: Am J Manag Care – ident: e_1_2_8_40_2 doi: 10.18553/jmcp.2009.15.9.728 – ident: e_1_2_8_39_2 doi: 10.1136/bmj.39553.670231.25 – ident: e_1_2_8_14_2 doi: 10.1111/j.1464-410X.2006.06035.x – ident: e_1_2_8_23_2 – ident: e_1_2_8_18_2 doi: 10.1111/j.1524-4733.2007.00213.x – ident: e_1_2_8_34_2 doi: 10.1007/s00228-008-0600-9 – ident: e_1_2_8_6_2 doi: 10.1046/j.1464-410x.2001.02228.x – volume: 6 start-page: S574 year: 2000 ident: e_1_2_8_9_2 article-title: Comorbidities associated with overactive bladder publication-title: Am J Manag Care – ident: e_1_2_8_2_2 doi: 10.1038/nrurol.2010.147 – ident: e_1_2_8_36_2 doi: 10.1016/S0002-9343(03)00362-0 – start-page: CD003781 issue: 4 year: 2006 ident: e_1_2_8_13_2 article-title: Anticholinergic drugs versus placebo for overactive bladder syndrome in adults publication-title: Cochrane Database Syst Rev – volume: 2 start-page: 9 year: 2010 ident: e_1_2_8_11_2 article-title: Recent advances in management of bladder overactivity publication-title: F1000 Med Rep doi: 10.3410/M2-9 – ident: e_1_2_8_42_2 doi: 10.1111/j.1464-410X.2009.09036.x – ident: e_1_2_8_31_2 doi: 10.1111/j.1471-0528.1997.tb12054.x – ident: e_1_2_8_32_2 doi: 10.1111/j.1464-410X.2009.09035.x – volume: 11 start-page: S121 year: 2005 ident: e_1_2_8_26_2 article-title: Persistence with overactive bladder pharmacotherapy in a Medicaid population publication-title: Am J Manag Care – ident: e_1_2_8_47_2 doi: 10.1016/j.urology.2010.07.275 – ident: e_1_2_8_41_2 doi: 10.1097/01.hjh.0000186832.41125.8a – ident: e_1_2_8_12_2 doi: 10.1016/S0090-4295(99)00492-6 – ident: e_1_2_8_4_2 doi: 10.1111/j.1368-5031.2005.00617.x – ident: e_1_2_8_7_2 – ident: e_1_2_8_20_2 doi: 10.1007/BF02850081 – ident: e_1_2_8_29_2 doi: 10.1111/j.1464-410X.2004.05255.x – ident: e_1_2_8_25_2 doi: 10.1111/j.1464-410X.2008.07769.x – ident: e_1_2_8_16_2 doi: 10.1016/j.eururo.2004.11.004 – ident: e_1_2_8_5_2 doi: 10.1046/j.1464-410x.2001.02228.x – ident: e_1_2_8_33_2 doi: 10.1111/j.1742-1241.2010.02626.x – ident: e_1_2_8_37_2 doi: 10.1007/s00198-009-0930-1 – ident: e_1_2_8_44_2 – reference: 24029333 - J Urol. 2013 Oct;190(4):1328 |
| SSID | ssj0014665 |
| Score | 2.5254147 |
| Snippet | Study Type – Therapy (prevalence)
Level of Evidence 2b
What's known on the subject? and What does the study add?
Persistence with long‐term medication in... Study Type--Therapy (prevalence) Level of Evidence 2b. What's known on the subject? and What does the study add? Persistence with long-term medication in... Study Type - Therapy (prevalence) Level of Evidence 2b What's known on the subject? and What does the study add? Persistence with long-term medication in... |
| SourceID | proquest pubmed pascalfrancis crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1767 |
| SubjectTerms | Administration, Oral Adult Age Factors antimuscarinic drugs Biological and medical sciences Bladder Chronic Disease Female Humans Longitudinal Studies Male Medical sciences Medication Adherence - statistics & numerical data Middle Aged Muscarinic Antagonists - administration & dosage Nephrology. Urinary tract diseases overactive bladder Patients persistence Prescription Drugs - administration & dosage solifenacin United Kingdom Urinary Bladder, Overactive - drug therapy Urinary incontinence Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland |
| Title | Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2012.11023.x https://www.ncbi.nlm.nih.gov/pubmed/22409769 https://www.proquest.com/docview/1767962319 https://www.proquest.com/docview/1237091988 |
| Volume | 110 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQQTx_VhfRPDapUnTNvWmooiiB3Fh8RKSJgFRd8XdBfXXO9N0KxUPIt5K2ylNMjP5mnz9hpBDFHCxXmeRS2EYhGM-kqVNI5FISJlFVjCNO7rXN9lFT1z2037Nf8J_YYI-RLPghpFR5WsMcG1G34NcRILFfWRocSS086SLeBKpW4iPbhslKbi1qioZTAC2t0k9Pz6oNVMtvOgRdJoP1S5-gqNtdFtNT-dL5HHasMBKeexOxqZbfnzTfPyfli-TxRrF0uPgditkxg1Wydx1vU-_Ru6RWI8OBC5FcamXIt8WEpRxlsJYPjxPoJ24eVTS8AfYOwX0TJFPqqsMTM0T5sTXI6pp74q6RpF5nfTOz-5OL6K6ikNUophbZGVsEumYxopIuXeeZ5oJY71LdCZizbk2mU3jxGkjrbUFM7LwgnPv0oI5nWyQ2cFw4LYIlQCPYKpl3JW5KEurufG5M-hUMeDYpEPy6YipspY4x0obT6r1qSMUdp3CrlNV16m3DmGN5UuQ-fiFzX7LKRpDngFsSwW8zu7US1SdGUaK5bhyB6i66JCD5jLENG7U6IEbTuAenuSA4wopO2QzeNfXwzkqlGVgnVc-8uvXVSeXvepw-8-WO2Qezwc2zy6ZHb9O3B5gsrHZr6LtE-TzJcQ |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5KCm0h9J1m2zRVoFcvlizbcm9tHmyTbA4hC0svQrIkCNluQrILbX99Zyyvi0MOoeRmsEZY0szo82j0DcBnInBxwRSJz3EZpOchUbXLE5kpdJlVUXFDJ7rjk2I0kYfTfNqWA6K7MJEfogu4kWU0_poMnALSt61cJpKnU0rREpTRLrIhAsrHVOCbyhnsnXZcUti2qSsZZRC499N67uypt1etX5kbnLYQ613cBUj7-LbZoA5ewGw1tJiXcjFcLuyw_nOL9fGBxv4SnrdAln2NmvcKHvn5a3gybo_q38APyq0nHUKtYhTtZZRyiz7KesdwOc9_LnGgdH5Us3gJ7DdDAM0opdQ0TpjZGbnF6y_MsMkR8x0p81uYHOyf7Y6StpBDUhOfW-JUajPluaGiSGXwQRSGS-uCz0whUyOEsYXL08wbq5xzFbeqClKI4POKe5NtwNr8cu43gSlESLjbcuHrUta1M8KG0lvSqxShbDaAcrVkum5ZzqnYxkz3_nakpqnTNHW6mTr9awC8k7yKTB_3kNnuaUUnKApEbrnEz9laqYluncON5iUF7xBYVwPY6V6jWdNZjZn7yyW2EVmJUK5SagDvonr961wQSVmB0mWjJPf-XP3tcNI8vv9vyU_wdHQ2PtbH30-OPsAzahOTe7ZgbXG99B8Roi3sdmN6fwFB_Cne |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3faxQxEB6khSKI1t-ntUbwdY9NNpvN-qbWo7a2iHhw-BKSTQKl9Xq0d6D9653Z7K1s6UMR3xY2s2ySmcm3ybffALwlARcfrcpCidMgA4-ZbnyZyUJjyqxVzS2d6B4dq_2pPJiVs47_RP_CJH2IfsONIqPN1xTgCx-vB7nMJM9nxNASRGgXxRjx5KZUGDsEkL71UlLYti0rmWwQtw9ZPTc-abBU3VvYSxy1mMpd3IRHh_C2XZ8mD-B03bNESzkdr5Zu3FxdE338P13fhvsdjGXvk989hDth_gi2jrqD-sfwg5j15EHoU4z2ehkRbjFDueAZTubJzxX2k06PGpZ-AfvNED4zIpTaNgUzd0ZJ8eIds2x6yEIvyfwEppNP3z_uZ10Zh6whNbfM69wVOnBLJZGqGKJQlkvnYyiskrkVwjrly7wI1mnvfc2drqMUIoay5sEWT2Fjfj4Pz4FpxEe41nIRmko2jbfCxSo48qocgWwxgmo9Y6bpNM6p1MaZGXzrSENDZ2joTDt05tcIeG-5SDoft7DZHThFbygU4rZS4uvsrL3EdKnh0vCKtu4QVtcjeNPfxqCmkxo7D-crbCOKCoFcrfUIniXv-vtwQRJlCq2r1kdu_brmw8G0vXzxz5avYevr3sR8-Xx8-BLuUpPE7NmBjeXFKrxCfLZ0u23g_QGtMCiW |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Persistence+with+prescribed+antimuscarinic+therapy+for+overactive+bladder%3A+a+UK+experience&rft.jtitle=BJU+international&rft.au=Wagg%2C+Adrian&rft.au=Compion%2C+Gerhard&rft.au=Fahey%2C+Amanda&rft.au=Siddiqui%2C+Emad&rft.date=2012-12-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=1464-4096&rft.eissn=1464-410X&rft.volume=110&rft.issue=11&rft.spage=1767&rft.epage=1774&rft_id=info:doi/10.1111%2Fj.1464-410X.2012.11023.x&rft.externalDBID=10.1111%252Fj.1464-410X.2012.11023.x&rft.externalDocID=BJU11023 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |